FORTE Trial Summary Report

Plixorafenib (FORE8394) Phase 2 Master Protocol for BRAF-Altered Cancers
NCT05503797 - View on ClinicalTrials.gov
📄

Trial Overview

Official TitleA Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations
Brief TitleFORTE: FORE8394 in Participants With Cancer Harboring BRAF Alterations
SponsorFORE Biotherapeutics, Inc.
Study TypeInterventional (Clinical Trial)
PhasePhase 2
DesignMaster Protocol / Basket Trial - 4 Sub-Protocols
StatusRecruiting
Enrollment Target~125 participants
📈

Key Efficacy Results (Phase 1/2a)

66.7%
ORR - CNS Tumors (MAPKi-naive)
13.9 mo
Median Duration of Response
>75%
Clinical Benefit Rate
41.7%
ORR - Other Solid Tumors
Tumor Category N ORR 95% CI Median DoR
Primary CNS V600 (MAPKi-naive) 9 66.7% [29.9-92.5] 13.9 mo (3.7-32.3)
- Low-grade glioma/Glioneuronal -- -- -- mPFS: Not Reached
- High-grade glioma (Grade 3-4) -- -- -- mPFS: 6.7 mo
Other Solid Tumors V600 24 41.7% -- 17.8 mo (3.7-59.2)
📊

Study Sub-Protocols (Cohorts)

Sub-Protocol Population Target N Response Criteria
A CNS Tumors BRAF V600 Primary CNS Tumors (recurrent/progressive) ~50 RANO
B Solid Tumors Other BRAF V600 Solid Tumors ~25 RECIST v1.1
C Rare Tumors Rare BRAF V600 Tumors (≤40,000 US patients/yr) ~25 RECIST v1.1
D BRAF Fusions BRAF Class 2 Fusions ~25 RECIST v1.1
💊

Treatment Regimen

DrugPlixorafenib (FORE8394 / PLX8394)
Dose900 mg QD (once daily, continuous)
PK BoosterCobicistat (in some cohorts)
RouteOral
MechanismNovel BRAF inhibitor - Dimer and Paradox Breaker. Disrupts RAF dimerization, prevents paradoxical activation. Targets both Class 1 (V600) mutations and Class 2 (fusions).
Key AdvantageNo MEK inhibitor combination required
🛡

Safety Profile

<2%
Discontinuation Rate (drug-related)
0
DLTs at RP2D
No
Paradoxical Activation
Common TEAEs Severity Grade 3+
LFT Elevations (ALT/AST)Grade 1-2Rare
FatigueGrade 10%
NauseaGrade 10%
DiarrheaGrade 10%
VomitingGrade 10%
Headache (CNS patients)Variable<5%
Compared to BRAF/MEK Inhibitor Combinations:
  • Lower incidence of rash
  • Reduced fever
  • Lower risk of intratumoral bleeding
  • Reduced cardiac, ocular, and growth effects
👤

Eligibility Criteria

Key Inclusion Criteria

  • Age ≥10 years
  • Weight ≥30 kg
  • Karnofsky (≥16 years) or Lansky (<16 years) Performance Score ≥60
  • Confirmed BRAF V600 mutation or BRAF fusion
  • Measurable disease per RECIST v1.1 or RANO
  • Prior therapy for advanced disease
  • ECOG performance status 0-1

Key Exclusion Criteria

  • Prior BRAF, MEK, or ERK inhibitor therapy
  • Colorectal adenocarcinoma
  • Pancreatic ductal adenocarcinoma
  • BRAF V600E cutaneous melanoma
  • Thyroid cancer (ATC/PTC)
  • NSCLC
  • Known NF-1 or RAS-related alterations
  • Active liver disease (HBV/HCV positive)
  • GI impairment affecting absorption
🎯

FDA Regulatory Status & Timeline

Sept 2022
Fast Track Designation
March 2023
Orphan Drug Designation
2024
Interim Analysis (n=25)
H2 2026
Topline Data Expected
5
TBD
NDA Submission
Fast TrackGranted September 2022 - Treatment of cancers harboring BRAF Class 1 (V600) and Class 2 alterations who have exhausted prior therapies
Orphan DrugGranted March 2023 - Treatment of primary brain and CNS malignancies
Approval PathwayAccelerated Approval based on ORR and Duration of Response
Confirmatory TrialPhase 3 design in planning
🌐

Study Locations

Total Sites54 activated
Countries9 countries (Global trial)
StatusRecruiting
🎯

Study Endpoints

Type Endpoint Assessment
Primary Overall Response Rate (ORR) BICR per RECIST v1.1 (solid) or RANO (CNS)
Primary Duration of Response (DoR) Time from first response to progression
Secondary Progression-Free Survival (PFS) --
Secondary Overall Survival (OS) --
Secondary Safety and Tolerability AE monitoring, lab assessments
Clinical Brief (Jun 2026) ← Back to FORTE Dashboard